Become a partner
Sanofi Pasteur Partnership Brochure
Click image to browse brochure
Useful link
Become a Partner
Sanofi Pasteur seeks alliances that will complement its own resources and share the company’s vision, values and standards of excellence.
Now, more than ever, it is clear that creative partnerships between academia, biotechnology companies, research foundations, government agencies and the pharmaceutical industry are necessary to meet the growing demand for new, more technologically challenging vaccines. At sanofi pasteur, our scientific and economic strengths allow us to develop alliances with organizations whose performance and values are aligned with our own. These partnerships cover a spectrum of activities ranging from discovery through production processes and marketing.
Fruitful collaborations have already been developed with entities offering a wide range of structures and missions:
- Major universities
- Institutes
- Government bodies
- Biotech firms
- Contract Research Organizations (CRO), to which we may assign responsibility for a specific clinical trial or study of production processes
Our unmatched expertise in every phase of vaccine development and delivery makes sanofi pasteur an ideal partner for organizations that want to bring new and evolving immunological products and vaccines to market. Our partners recognize that we can optimize the use of early and late-stage research and development, industrial, operational or marketing resources. Together, we can accelerate the development and distribution of new and innovative products.
Partnership Opportunities
Sanofi Pasteur is interested in potential partnering opportunities in the field of active and passive human immunization, including:
Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases
Novel antigens for vaccine development
Monoclonal antibodies, including antigens as targets for monoclonal antibody development
Antigen discovery and characterization
Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies
Agents to enhance vaccine immune responses – such as adjuvants and immunomodulators
Adjuvants, particularly those that drive Th1 and Th2 immune responses
Vaccine vectors intended to enhance or modify immune responses
Characterization, modulation and assay of protective imune responses
Areas of basic immunology applicable to vaccine development, such as studies of innate immunity, immune escape mechanisms, and immunoregulation
New vaccine delivery systems
New ways to administer vaccines
Vaccine vectors suitable for nasal or oral use
Tools for improving vaccine and monoclonal antibody research, development and production
Animal models of human diseases
Development and application of new technologies in the areas of genomics and proteomics
Bioinformatics techniques for data handling and analysis
Prokaryotic or eukaryotic cell lines for antigen production
Fermentor and bioreactor technology
Downstream processing and purification processes
Preservatives and stabilizers
Identification of biological markers for evaluating the efficacy of prophylactic or therapeutic interventions for infectious diseases
Epidemiological studies relevant to the use of vaccines and immunotherapeutics
